Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior-A case report.

AL amyloidosis case report light chain proximal tubulopathy monoclonal gammopathy of renal significance

Journal

EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 06 08 2022
revised: 02 08 2022
accepted: 12 08 2022
entrez: 5 12 2022
pubmed: 6 12 2022
medline: 6 12 2022
Statut: epublish

Résumé

Due to differences in the protein folding mechanisms, it is exceedingly rare for amyloid light chain (AL) amyloidosis and monoclonal gammopathy of renal significance (MGRS) to coexist. We herein report the first case of concurrent AL amyloidosis and a subclass of MGRS, light chain proximal tubulopathy (LCPT). The 53-year-old female was diagnosed with smoldering myeloma immunoglobulin G

Identifiants

pubmed: 36467828
doi: 10.1002/jha2.555
pii: JHA2555
pmc: PMC9713218
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1377-1380

Informations de copyright

© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

The authors declare they have no conflicts of interest.

Références

Orphanet J Rare Dis. 2012 Aug 21;7:54
pubmed: 22909024
Blood. 2018 Oct 4;132(14):1478-1485
pubmed: 30012636
N Engl J Med. 1991 Jun 27;324(26):1845-51
pubmed: 1904132
Clin Exp Nephrol. 2009 Dec;13(6):671-6
pubmed: 19728011
Nephrol Dial Transplant. 2010 Apr;25(4):1340-3
pubmed: 20061318
Blood. 2020 Oct 1;136(14):1645-1656
pubmed: 32559766
Nat Rev Nephrol. 2019 Jan;15(1):45-59
pubmed: 30510265
Kidney Int. 2022 Jan;101(1):152-163
pubmed: 34767832
Am J Hematol. 2017 Aug;92(8):739-745
pubmed: 28383130
Mod Pathol. 2011 Nov;24(11):1462-9
pubmed: 21701535
Histopathology. 1986 Oct;10(10):1065-76
pubmed: 3096869
J Hepatol. 1991 Jan;12(1):75-82
pubmed: 1901075
Histopathology. 1986 Oct;10(10):1057-64
pubmed: 3096868
Int J Clin Exp Pathol. 2019 Jun 01;12(6):2279-2283
pubmed: 31934052

Auteurs

Simone Feurstein (S)

Department of Internal Medicine, Section of Hematology, Oncology & Rheumatology University Hospital Heidelberg Heidelberg Germany.

Julian Zoller (J)

Department of Internal Medicine, Section of Hematology, Oncology & Rheumatology University Hospital Heidelberg Heidelberg Germany.

Constantin Schwab (C)

Institute of Pathology University Hospital Heidelberg Heidelberg Germany.

Sarah Schreiner (S)

Department of Internal Medicine, Section of Hematology, Oncology & Rheumatology University Hospital Heidelberg Heidelberg Germany.

Heiko Mundt (H)

Department of Internal Medicine, Section of Nephrology University Hospital Heidelberg Heidelberg Germany.

Iris Breitkreutz (I)

Department of Internal Medicine, Section of Hematology, Oncology & Rheumatology University Hospital Heidelberg Heidelberg Germany.

Brigitte Schneider (B)

Department of Internal Medicine, Section of Hematology, Oncology & Rheumatology University Hospital Heidelberg Heidelberg Germany.

Jörg Beimler (J)

Department of Internal Medicine, Section of Nephrology University Hospital Heidelberg Heidelberg Germany.

Martin Zeier (M)

Department of Internal Medicine, Section of Nephrology University Hospital Heidelberg Heidelberg Germany.

Rüdiger Waldherr (R)

Institute of Pathology University Hospital Heidelberg Heidelberg Germany.

Stefan Gröschel (S)

Oncology Center Worms Worms Germany.

Carsten Müller-Tidow (C)

Department of Internal Medicine, Section of Hematology, Oncology & Rheumatology University Hospital Heidelberg Heidelberg Germany.

Stefan O Schönland (SO)

Department of Internal Medicine, Section of Hematology, Oncology & Rheumatology University Hospital Heidelberg Heidelberg Germany.

Ute Hegenbart (U)

Department of Internal Medicine, Section of Hematology, Oncology & Rheumatology University Hospital Heidelberg Heidelberg Germany.

Classifications MeSH